Evidence map›Paper›PMID 29026085›Full record

ArticleNature communications2017

EZH2 enables germinal centre formation through epigenetic silencing of CDKN1A and an Rb-E2F1 feedback loop.

Wendy Béguelin, Martín A Rivas, María T Calvo Fernández, Matt Teater, Alberto Purwada, David Redmond, Hao Shen, Matt F Challman, Olivier Elemento, Ankur Singh and 1 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 118 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
118citing papers in PubMed, 1 pooled it
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

118 citing papers in PubMed, 1 synthesis or guideline pooled it, 182 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. EZH2 coordinates memory B-cell programming and recall responses.Journal of immunology (Baltimore, Md. : 1950) · 2025
    Article
  18. Article
  19. Review
  20. Review

58 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Wendy BéguelinDivision of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY, 10021, USA. web2002@med.cornell.edu.
Martín A RivasDivision of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY, 10021, USA.
María T Calvo FernándezDivision of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY, 10021, USA.
Matt TeaterDivision of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY, 10021, USA.
Alberto PurwadaMeinig School of Biomedical Engineering, Cornell University, Ithaca, NY, 14853, USA.
David RedmondInstitute for Computational Biomedicine, Weill Cornell Medicine, Cornell University, New York, NY, 10021, USA.
Hao ShenDivision of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY, 10021, USA.
Matt F ChallmanDivision of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY, 10021, USA.
Olivier ElementoInstitute for Computational Biomedicine, Weill Cornell Medicine, Cornell University, New York, NY, 10021, USA.
Ankur SinghMeinig School of Biomedical Engineering, Cornell University, Ithaca, NY, 14853, USA. as2833@cornell.edu.ORCID http://orcid.org/0000-0003-3357-496X
Ari M MelnickDivision of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY, 10021, USA. amm2014@med.cornell.edu.
Cornell University · US

Funding

The identification and validation of mechanisms and biomarkers for relapse in diffuse large B-cell lymphoma (Administrative Supplement)R01CA194547 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI ELEMENTO, OLIVIER, TAM, WAYNE · 2015 to 2019
$2.6M
Targeting EZH2 in Germinal Center Derived B-Cell LymphomaR01CA187109 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI MELNICK, ARI M. · 2014 to 2017
$1.8M
LETSSGo: Lymphoma-on-chip Engineered Technology for Single-Organoid Sequencing and GenomicsR33CA212968 · NCI · CORNELL UNIVERSITY · PI SINGH, ANKUR · 2017 to 2019
$1.1M
NCI NIH HHS R01 CA187109NCI NIH HHS R01 CA194547NCI NIH HHS R33 CA212968
6 · The paper itself

Abstract

The EZH2 histone methyltransferase is required for B cells to form germinal centers (GC). Here we show that EZH2 mediates GC formation through repression of cyclin-dependent kinase inhibitor CDKN1A (p21

Indexed as

AnimalsCell ProliferationCyclin-Dependent Kinase Inhibitor p21E2F1 Transcription FactorEnhancer of Zeste Homolog 2 ProteinEpigenesis, GeneticFeedback, PhysiologicalG1 Phase Cell Cycle CheckpointsGene SilencingGerminal CenterMiceCyclin-Dependent Kinase Inhibitor p21E2f1 protein, mouseE2F1 Transcription FactorEnhancer of Zeste Homolog 2 ProteinEzh2 protein, mouse

Identifiers

PMID29026085
PMCPMC5638898
OpenAlexW2762023120

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.